[Use of intravitreal bevacizumab for macular edema in branch retinal vein occlusion].
To study the effect of intravitreal bevacizumab on macular edema secondary to branch retinal vein occlusion (BRVO). 6 eyes of 5 patients averaging 70 years, who had received either retinal photocoagulation or trans-tenon retrobulbar triamcinolone injections or both, but in whom the macular edema remained. There was an average of 337 days from BRVO onset to injection of bevacizumab. Corrected vision and foveal thickness were measured. Visual acuity and foveal thickness improved significantly one month after injection. Intravitreal injection of bevacizumab is effective for a short time.